Anthera Pharmaceuticals Company Profile (NASDAQ:ANTH)

Analyst Ratings

Consensus Ratings for Anthera Pharmaceuticals (NASDAQ:ANTH) (?)
Ratings Breakdown: 1 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $10.80 (249.51% upside)

Analysts' Ratings History for Anthera Pharmaceuticals (NASDAQ:ANTH)
Show:
DateFirmActionRatingPrice TargetActions
7/8/2016HC WainwrightInitiated CoverageBuy$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/30/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/20/2016FBR & CoReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/11/2016Piper Jaffray Cos.Lower Price TargetOverweight$14.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/19/2016Citigroup Inc.Lower Price Target$15.00 -> $11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/8/2015SunTrust Banks Inc.Initiated CoverageBuy$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for Anthera Pharmaceuticals (NASDAQ:ANTH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/9/2016Q1($0.28)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q4($0.27)($0.18)$1.92 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2015Q315($0.25)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q2($0.28)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.31)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/16/2015($0.33)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2014($0.39)($0.31)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/28/2014($0.49)($0.34)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q114($0.46)($0.39)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2014($0.47)($0.48)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/26/2013Q412($0.15)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Anthera Pharmaceuticals (NASDAQ:ANTH)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.30)($0.30)($0.30)
Q2 20162($0.30)($0.29)($0.30)
Q3 20162($0.30)($0.29)($0.30)
Q4 20162($0.28)($0.26)($0.27)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Anthera Pharmaceuticals (NASDAQ:ANTH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Anthera Pharmaceuticals (NASDAQ:ANTH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
11/13/2015Colin HislopinsiderSell12,500$5.31$66,375.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2015Colin HislopInsiderSell5,000$5.38$26,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/12/2015Debra OdinkCTOSell1,205$6.15$7,410.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/24/2013David E ThompsonDirectorBuy12,500$0.53$6,625.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/31/2013Bogdan DziurzynskiDirectorBuy1,250$0.59$737.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/30/2013Orbimed Advisors LlcDirectorBuy712,500$0.66$470,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/25/2013Orbimed Advisors LlcDirectorBuy220,250$0.65$143,162.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Anthera Pharmaceuticals (NASDAQ:ANTH)
DateHeadline
07/22/16 10:43 AMEarnings Focus and Crowd Sourced Sentiment Review for Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - TGP
07/21/16 08:06 PMAnthera Pharmaceuticals Inc (NASDAQ:ANTH) Realized Volatility Hits An Elevated Level - CML News
07/21/16 02:31 PMAnthera Pharmaceuticals, Inc. (ANTH) Current Analyst Ratings - Fiscal Standard
07/19/16 07:55 PMShares Losing Ground in Session: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - TGP
07/19/16 02:30 PMAnthera Pharmaceuticals Incorporated (NASDAQ:ANTH) Sellers Increased By 9.1% Their Shorts - Consumer Eagle
07/19/16 02:30 PMEquity Roundup: Stock Performance Focus on Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Press Telegraph
07/19/16 10:58 AMETF’s with exposure to Anthera Pharmaceuticals, Inc. : July 19, 2016 -
07/18/16 02:34 PMInvestor Watch: Volatility Recap on Shares of: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Engelwood Daily
07/17/16 07:15 AMShares Moving Down on the Week: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Engelwood Daily
07/17/16 07:15 AMShares Experiencing a Downtrend: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - TGP
07/16/16 02:30 PMAnthera Pharmaceuticals Incorporated (NASDAQ:ANTH) Short Interest Decreased By 1.01% - Consumer Eagle
07/15/16 01:05 PMGlobal Multiple Myeloma (Kahler Disease) Pipeline 2016 Market Research Review
07/14/16 02:31 PMEye on Stock Volatility for: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Engelwood Daily
07/14/16 02:31 PMAnthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/13/16 02:33 PMAnthera Pharmaceuticals Inc (NASDAQ:ANTH) Sentiment Report - Consumer Eagle
07/12/16 06:58 AMAnalyst Target and Average Rating Watch: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Press Telegraph
07/12/16 06:58 AMTrading Performance and Target Watch for Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Press Telegraph
07/12/16 06:58 AMAnthera Pharmaceuticals Inc. (NASDAQ:ANTH) announced results from interim analysis of the Phase 2 BRIGHT-SC ... - Inside Trade
07/11/16 07:33 PMAnthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/11/16 07:19 AMCompany Shares of Anthera Pharmaceuticals (NASDAQ:ANTH) Rally 19.81% - TheFounders Daily
07/10/16 07:15 AMIs $14 Within Reach For Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH)? - Investor Newswire
07/09/16 10:36 AMNews Review: Anthera Pharmaceuticals Inc (NASDAQ:ANTH), Polycom Inc (NASDAQ:PLCM), NeoGenomics, Inc ... - iStreetWire
07/08/16 02:31 PMWall Street Ratings and Target Price Views on Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Telanagana Press
07/08/16 01:30 PMStreet Talk: Apple, Amazon & more -
07/08/16 06:10 AMCoverage initiated on Anthera Pharma by H.C. Wainwright -
07/07/16 02:29 PMAnthera Pharmaceuticals, Inc. Stock Momentum at Critical Inflection Point - CML News
07/07/16 10:27 AMAnthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Stock Update: Check on Ratings and Target Price - Telanagana Press
07/06/16 07:19 AMStock Rating Watch and Earnings Insight for Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Press Telegraph
07/05/16 02:29 PMCan Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Improve on the Earnings Front? - Engelwood Daily
07/05/16 07:18 AMShare Performance Recap for: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Press Telegraph
07/02/16 02:31 PMAnthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Expected to Reach Highs Of $14 - Investor Newswire
06/29/16 07:38 PMCompany Update (NASDAQ:ANTH): Anthera Pharmaceuticals Inc Provides Clinical Program Updates for Blisibimod ... - Smarter Analyst
06/29/16 02:29 PMShare Update and Earnings Review for Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Press Telegraph
06/29/16 10:57 AMANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
06/29/16 10:43 AMPre-Open Stock Movers 06/29: (TSRO) (DRII) (PVTB) Higher; (GALE) (LPCN) (ESPR) Lower (more...)
06/28/16 07:52 PMAnthera Pharmaceuticals Inc.: Anthera Provides Clinical Program Updates for Blisibimod and Sollpura® - The Wall Street Transcript
06/28/16 04:31 PMAnthera Provides Clinical Program Updates for Blisibimod and Sollpura® - [at noodls] - Positive trends from BRIGHT-SC proof-of-concept study - study to continue SOLUTION study with Sollpura completed patient screening ahead of schedule - data in 2016 First patients screened in Phase 3 CHABLIS ...
06/28/16 02:43 PMAnthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Earnings Glance and Target Price Review - Engelwood Daily
06/28/16 02:43 PMStock Volatility in Review: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Engelwood Daily
06/27/16 07:15 AMNext Weeks Broker Price Targets For Anthera Pharmaceuticals, Inc. (ANTH) - Fiscal Standard
06/26/16 07:32 AMStrong Sell Calls Recommendations For Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) At 0 - Investor Newswire
06/24/16 07:41 PMMyocardial Infarction Therapeutics Market Growth 2016 Forecast to 2022
06/24/16 02:29 PMAnthera Pharmaceuticals, Inc. (ANTH) Updated Price Targets - FTSE News
06/24/16 08:46 AMThe 2016 Report on Myocardial Infarction World Market Segmentation and Major Players Analysis 2022
06/22/16 07:39 PMAnthera Pharmaceuticals, Inc. (NasdaqGM:ANTH) Stock Momentum Hits Weakness - CML News
06/21/16 07:18 AMRecently Issued Stock Ratings For Anthera Pharmaceuticals, Inc. (ANTH) - Fiscal Standard
06/20/16 08:58 AMStock Highlights: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), American Water Works Company, Inc. (NYSE:AWK ... - KC Register
06/19/16 07:13 AMThis Weeks Broker Views For Anthera Pharmaceuticals, Inc. (ANTH) - Fiscal Standard
06/15/16 07:36 PMRecent Study on Exocrine Pancreatic Insufficiency Market with Size and Share Deep Analysis
06/15/16 07:36 PMAnthera Pharmaceuticals : Announces Presentation at JMP Securities Life Sciences Conference

Social

About Anthera Pharmaceuticals

Anthera Pharmaceuticals logoAnthera Pharmaceuticals Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. The Company's primary Phase 3 product candidate blisibimod targets elevated levels of Bcell activating factor (BAFF) which has been associated with a variety of Bcell mediated autoimmune diseases including systemic lupus erythematosus or lupus IgA nephropathy lupus nephritis multiple myeloma and others. The Company's second product candidate Sollpura (liprotamase) is a Phase III investigational pancreatic enzyme replacement therapy (PERT) intended for the treatment of patients with exocrine pancreatic insufficiency (EPI) often seen in patients with cystic fibrosis and other conditions.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ANTH
  • CUSIP:
Key Metrics:
  • Previous Close: $3.09
  • 50 Day Moving Average: $3.30
  • 200 Day Moving Average: $3.44
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $126.65M
  • Beta: 1.95
  • Current Year EPS Consensus Estimate: $-1.25 EPS
  • Next Year EPS Consensus Estimate: $-1.31 EPS
Additional Links:
Anthera Pharmaceuticals (NASDAQ:ANTH) Chart for Saturday, July, 23, 2016